What is Hims & Hers offering as an alternative to Wegovy?

Hims & Hers is offering a compounded version of Novo Nordisk's Wegovy pill at an introductory price of $49 per month.

How did Novo Nordisk and Eli Lilly shares react to the Hims & Hers announcement?

Shares of Novo Nordisk and Eli Lilly dropped following the announcement due to concerns about emerging lower-cost alternatives impacting profit margins.

What are the concerns surrounding compounded weight-loss drugs?

Concerns include the legality of compounded versions, potential impact on branded drug margins, and questions about regulatory enforcement by the FDA.

Home / Business and Economy / Hims & Hers Launches Wegovy Competitor at $49

Hims & Hers Launches Wegovy Competitor at $49

5 Feb

•

Summary

Hims & Hers introduces compounded Wegovy at $49 monthly.
Competitor launch causes Novo Nordisk and Eli Lilly shares to drop.
Concerns rise over margin protection amid emerging alternatives.

Hims & Hers Launches Wegovy Competitor at $49

Hims & Hers announced it will offer a compounded version of Novo Nordisk's Wegovy, a popular weight-loss medication, at an introductory price of $49 per month. This new offering aims to provide personalized treatment strategies, similar to its approach with compounded injectable weight-loss drugs.

The introduction of this lower-cost alternative has sent ripples through the pharmaceutical industry, causing shares of Novo Nordisk and competitor Eli Lilly to fall. Investors are concerned about how these major drugmakers will protect their profit margins as more affordable options become available in the market.

Industry analysts express varied views, with some highlighting the potential for compounded versions to address specific patient needs, such as lower or intermittent dosing. Others question the legality and long-term implications of such offerings, noting that legal challenges and regulatory oversight from the FDA could be forthcoming.